| 1. |
- Aabenhus, Rune, et al.
(författare)
-
First attempt to produce experimental Campylobacter concisus infection in mice
- 2008
-
Ingår i: World Journal of Gastroenterology. - : Baishideng Publishing Group Inc.. - 1007-9327. ; 14:45, s. 6954-6959
-
Tidskriftsartikel (refereegranskat)abstract
- AIM: To infect mice with atypical Campylobacter concisus (C concisus) for the first time. METHODS: Three separate experiments were conducted in order to screen the ability of five clinical C concisus isolates of intestinal origin and the ATCC 33237 type strain of oral origin to colonize and produce infection in immunocompetent BALB/cA mice. The majority of the BALB/cA mice were treated with cyclophosphamide prior to C concisus inoculation to suppress immune functions. Inoculation of C concisus was performed by the gastric route. RESULTS: C concisus was isolated from the liver, ileum and jejunum of cyclophosphamide-treated mice in the first experiment. No C concisus strains were isolated in the two subsequent experiments. Mice infected with C concisus showed a significant loss of body weight from day two through to day five of infection but this decreased at the end of the first week. Histopathologicalexamination did not consistently find signs of inflammation in the gut, but occasionally microabscesses were found in the liver of infected animals. CONCLUSION: Transient colonization with C concisus was observed in mice with loss of body weight. Future studies should concentrate on the first few days after inoculation and in other strains of mice. (C) 2008 The WJG Press. All rights reserved.
|
|
| 2. |
- Janulaityte-Gunther, Daiva, et al.
(författare)
-
Combined serum IgG response to Helicobacter pylori VacA and CagA predicts gastric cancer
- 2007
-
Ingår i: Pathogens and Disease. - 2049-632X. ; 50:2, s. 220-225
-
Tidskriftsartikel (refereegranskat)abstract
- Helicobacter pylori is a major factor for the development of gastric cancer. The aim of this study was to define serum antibody patterns associated with H. pylori infection in patients with gastric cancer using a Western blot technique. Serum samples collected from 115 patients with gastric cancer and 110 age- and gender-matched patients without gastrointestinal diseases were tested for IgG antibodies to H. pylori antigens (outer membrane proteins and whole cell preparations). No significant differences were found between patients with and without gastric cancer using outer membrane proteins (82% and 73%, P > 0.05) or whole cell antigens (84% and 76%, P > 0.05), respectively. The significant differences between patients with and without gastric cancer were associated with bands of 94 kDa (54% and 20%, P < 0.001) and 30 kDa (65% and 44%, P < 0.01). A combination of antibodies to 85 kDa (VacA) and 120 kDa (CagA) was significantly (P < 0.01) more frequent in gastric cancer patients than in patients without gastric cancer. The detection of antibodies to 94- and 30-kDa bands, in association with the determination of serum antibodies to CagA(+)/VacA(+), may have a prospective value in assessment of the risk of developing of gastric cancer.
|
|
| 3. |
- Kupcinskas, Limas, et al.
(författare)
-
Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study
- 2008
-
Ingår i: Phytomedicine. - : Elsevier BV. - 0944-7113. ; 15:6-7, s. 391-399
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: The aim of this study was to evaluate the efficacy of the natural antioxidant astaxanthin in functional dyspepsia in different doses and compared with placebo. Design: The study was a controlled, prospective, randomized, and double blind trial. Participants: Patients with functional dyspepsia, divided into three groups with 44 individuals in each group (placebo, 16 mg, or 40 mg astaxanthin, respectively). Interventions: Participants were asked to accept gastroscopy before treatment, together with questionnaires: GSRS and SF-36. Urea breath test (UBT) was done before the treatment. Main outcome: The primary objective was to test the hypothesis that the antioxidant astaxanthin at two doses regimens compared to placebo should ameliorate gastrointestinal discomfort measured as GSRS in patients with functional dyspepsia, who were either positive or negative for Helicobacter pylori, after 4 weeks of treatment. Results: At the end of therapy (week 4) no difference between the three treatment groups was observed regarding mean Gastrointestinal Symptom Rating Scale (GSRS) scores of abdominal pain, indigestion and reflux syndromes. The same results were observed at the end of follow-up. However reduction of reflux syndrome before treatment to week 4 was significantly pronounced in the higher (40 mg) dose compared to the other treatment groups (16 mg and placebo, p = 0.04). Conclusion: In general, no curative effect of astaxanthin was found in functional dyspepsia patients. Significantly greater reduction of reflux symptoms were detected in patients treated with the highest dose of the natural antioxidant astaxanthin. The response was more pronounced in H. pylori-infected patients. (c) 2008 Elsevier GmbH. All rights reserved.
|
|
| 4. |
- Percival Andersen, Leif, et al.
(författare)
-
Gastric inflammatory markers and interleukins in patients with functional dyspepsia treated with astaxanthin
- 2007
-
Ingår i: Pathogens and Disease. - 2049-632X. ; 50:2, s. 244-248
-
Tidskriftsartikel (refereegranskat)abstract
- The chronic active inflammation caused by Helicobacter pylori is dominated by neutrophils, macrophages, lymphocytes and plasma cells. Several interleukins are involved in the inflammatory process. The aim of this study was to investigate the effect of astaxanthin on gastric inflammation in patients with functional dyspepsia. Forty-four consecutive patients were included, and biopsies were examined for IL-4, IL-6, IL-8, IL-10, interferon-gamma, CD4, CD8, CD14, CD19, CD25 and CD30. Patients were randomized: 21 patients were treated with 40 mg of astaxanthin daily, and 23 patients were treated with a placebo. There was a significant decrease in gastric inflammation in H. pylori-positive patients from both groups. There were no significant changes in the density of H. pylori or in any of the interleukins during or after treatment. There was a significant up-regulation of CD4 and down-regulation of CD8 in patients with H. pylori treated with astaxanthin. Astaxanthin had an effect on the inflammation and on the density of H. pylori in mice in a study where the diet could be standardized without antioxidants (Bennedsen et al., 1999). These dietary conditions are impossible in studies involving humans, and may be due to the minor effect when the host have access to antioxidants in their diet.
|
|
